Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FUROSEMIDE | Epic Pharma | N-018569 RX | 1982-01-01 | 3 products |
FUROSEMIDE | Fresenius Kabi | N-018902 RX | 1984-05-22 | 1 products |
FUROSEMIDE | Hikma Pharmaceuticals | N-018267 RX | 1982-01-01 | 1 products |
FUROSEMIDE | Hikma Pharmaceuticals | N-018823 RX | 1983-11-10 | 2 products |
FUROSEMIDE | Hospira | N-018667 RX | 1982-05-28 | 1 products |
FUROSCIX | scPharmaceuticals | N-209988 RX | 2022-10-07 | 1 products, RLD, RS |
LASIX | Validus Pharmaceuticals | N-016273 RX | 1982-01-01 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
14-panel toxicology medicated collection system | ANDA | 2022-03-29 |
active-medicated specimen collection kit | ANDA | 2014-03-20 |
diascreen 12-panel medicated collection system | ANDA | 2022-02-25 |
furoscix | New Drug Application | 2024-08-15 |
furosemide | New Drug Application | 2024-10-29 |
lasix | New Drug Application | 2023-02-13 |
rx-specimen collection kit | ANDA | 2018-02-22 |
toxicology medicated collection system | ANDA | 2022-04-05 |
toxycology medicated collection system | ANDA | 2022-02-25 |
udsx medicated system | unapproved drug other | 2024-09-10 |
Code | Description |
---|---|
J1940 | Injection, furosemide, up to 20 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart failure | D006333 | HP_0001635 | I50 | 14 | 30 | 31 | 37 | 37 | 136 |
Renal insufficiency | D051437 | HP_0000083 | N19 | 3 | 4 | 5 | 6 | 8 | 25 |
Hypertension | D006973 | EFO_0000537 | I10 | 1 | 3 | 4 | 7 | 10 | 24 |
Acute kidney injury | D058186 | HP_0001919 | N17 | 1 | 3 | 3 | 5 | 14 | 24 |
Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 3 | 3 | 7 | 5 | 18 |
Chronic renal insufficiency | D051436 | — | N18 | 1 | 2 | 2 | 7 | 2 | 14 |
Critical illness | D016638 | — | — | — | 2 | 2 | 1 | 8 | 12 |
Iron overload | D019190 | — | — | 1 | 1 | 2 | 4 | 3 | 11 |
Wounds and injuries | D014947 | — | T14.8 | — | 2 | — | 2 | 7 | 11 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | 1 | 3 | 5 | 10 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dyspnea | D004417 | HP_0002094 | R06.0 | 4 | 3 | 4 | — | — | 8 |
Warts | D014860 | — | B07 | — | 1 | 2 | — | 2 | 5 |
Covid-19 | D000086382 | — | — | — | 1 | 1 | — | 3 | 4 |
Syndrome | D013577 | — | — | — | 1 | 1 | — | 2 | 4 |
Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 3 | — | 1 | 4 |
Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | 2 | — | 2 | 4 |
Bronchiolitis | D001988 | HP_0011950 | — | 1 | 1 | 1 | — | — | 3 |
Hypernatremia | D006955 | HP_0003228 | E87.0 | — | — | 1 | — | 2 | 3 |
Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | 2 | — | 1 | 3 |
Nephrolithiasis | D053040 | — | N20.0 | — | — | 2 | — | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 18 | 1 | — | — | 3 | 21 |
Neoplasms | D009369 | — | C80 | 4 | 2 | — | — | — | 5 |
Acute lung injury | D055371 | EFO_0004610 | — | — | 1 | — | — | 3 | 4 |
Sepsis | D018805 | HP_0100806 | A41.9 | — | 1 | — | — | 3 | 4 |
Leukemia | D007938 | — | C95 | 2 | 1 | — | — | 1 | 3 |
Inflammation | D007249 | MP_0001845 | — | 1 | 1 | — | — | 2 | 3 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 1 | — | — | — | 2 |
Myelodysplastic syndromes | D009190 | — | D46 | 2 | 1 | — | — | — | 2 |
Multiple myeloma | D009101 | — | C90.0 | 2 | 1 | — | — | — | 2 |
Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dehydration | D003681 | — | E86.0 | 1 | — | — | — | 4 | 5 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | 2 | — | — | — | 1 | 3 |
Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | — | — | — | 1 | 2 |
Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
Stroke | D020521 | EFO_0000712 | I63.9 | 1 | — | — | — | — | 1 |
Food-drug interactions | D018565 | — | — | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
Peritoneal neoplasms | D010534 | — | — | 1 | — | — | — | — | 1 |
Crush injuries | D000071576 | — | T14.8 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | — | 3 | 3 |
Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | — | — | 3 | 3 |
Septic shock | D012772 | — | A48.3 | — | — | — | — | 3 | 3 |
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
Pulmonary arterial hypertension | D000081029 | — | — | — | — | — | — | 2 | 2 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 2 | 2 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 2 | 2 |
Fluid therapy | D005440 | — | — | — | — | — | — | 2 | 2 |
Shock | D012769 | — | R57.1 | — | — | — | — | 2 | 2 |
Drug common name | Furosemide |
INN | furosemide |
Description | Furosemide is a chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure. It has a role as a xenobiotic, an environmental contaminant and a loop diuretic. It is a sulfonamide, a chlorobenzoic acid and a member of furans. |
Classification | Small molecule |
Drug class | diuretics (furosemide type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl |
PDB | — |
CAS-ID | 54-31-9 |
RxCUI | — |
ChEMBL ID | CHEMBL35 |
ChEBI ID | 47426 |
PubChem CID | 3440 |
DrugBank | DB00695 |
UNII ID | 7LXU5N7ZO5 (ChemIDplus, GSRS) |